Tokyo, Oct. 20 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059453) titled 'Tirzepatide's Assessment on Satiety and Treatment Experience' on Oct. 20.
Study Type:
Interventional
Study Design:
Basic Design - Single arm
Randomization - Non-randomized
Blinding - Open -no one is blinded
Control - Historical
Primary Sponsor:
Institute - Kimitsu Chuo Hospital
Condition:
Condition - type 2 diabetes mellitus
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - evaluating the impact on eating behavior of T2DM patient.
Basic objectives2 - Safety,Efficacy
Intervention:
Interventions/Control_1 - we prescribed self-injection 2.5 mg Tirzepatide per week. The prescribing physician will determine whether to increase the dose based on side effects and treatment efficacy at intervals of 4 weeks or longer, with the maximum increase being up to 15 mg per week.
Eligibility:
Age-lower limit - 18
years-old
=
Gender - Male and Female
Key inclusion criteria - T2DM patients who agreed on prescription of Tirzepatide
Key exclusion criteria - who disagreed Tirzepatide treatment
Target Size - 50
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2023 Year 04 Month 01 Day
Date of IRB - 2023 Year 11 Month 15 Day
Anticipated trial start date - 2023 Year 05 Month 01 Day
Last follow-up date - 2025 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067963
Disclaimer: Curated by HT Syndication.
